Stock Research for SRNE

SRNE

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

SRNE Stock Chart & Research Data

The SRNE chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the SRNE chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


SRNE Due diligence Resources & Stock Charts

The SRNE stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View SRNE Detailed Price Forecast - CNN Money CNN View SRNE Detailed Summary - Google Finance
Yahoo View SRNE Detailed Summary - Yahoo! Finance Zacks View SRNE Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View SRNE Trends & Analysis - Trade-Ideas Barrons View SRNE Major Holders - Barrons
NASDAQ View SRNE Call Transcripts - NASDAQ Seeking View SRNE Breaking News & Analysis - Seeking Alpha
Spotlight View SRNE Annual Report - CompanySpotlight.com OTC Report View SRNE OTC Short Report - OTCShortReport.com
TradeKing View SRNE Fundamentals - TradeKing Charts View SRNE SEC Filings - Bar Chart
WSJ View Historical Prices for SRNE - The WSJ Morningstar View Performance/Total Return for SRNE - Morningstar
MarketWatch View the Analyst Estimates for SRNE - MarketWatch CNBC View the Earnings History for SRNE - CNBC
StockMarketWatch View the SRNE Earnings - StockMarketWatch MacroAxis View SRNE Buy or Sell Recommendations - MacroAxis
Bullish View the SRNE Bullish Patterns - American Bulls Short Pains View SRNE Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View SRNE Stock Mentions - StockTwits PennyStocks View SRNE Stock Mentions - PennyStockTweets
Twitter View SRNE Stock Mentions - Twitter Invest Hub View SRNE Investment Forum News - Investor Hub
Yahoo View SRNE Stock Mentions - Yahoo! Message Board Seeking Alpha View SRNE Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for SRNE - SECform4.com Insider Cow View Insider Transactions for SRNE - Insider Cow
CNBC View SRNE Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for SRNE - OTC Markets
Yahoo View Insider Transactions for SRNE - Yahoo! Finance NASDAQ View Institutional Holdings for SRNE - NASDAQ


Stock Charts

FinViz View SRNE Stock Insight & Charts - FinViz.com StockCharts View SRNE Investment Charts - StockCharts.com
BarChart View SRNE Stock Overview & Charts - BarChart Trading View View SRNE User Generated Charts - Trading View




Latest Financial News for SRNE


Sorrento Therapeutics Closes Five-Year Term Loan Financing for Up to $150 Million
Posted on Thursday November 08, 2018

Sorrento Therapeutics, Inc. (SRNE), a clinical-stage immunotherapy biotech company, announces the closing of a debt financing for up to $150 million. The financing is being provided by funds and accounts managed by Oaktree Capital Management, L.P. (“Oaktree”), a leading global investment firm.


Sorrento Therapeutics Anti-CEA CAR-T Demonstrates Significant Therapeutic Activity With Increased Overall Survival in Pancreatic Cancer Patients With Liver Metastases
Posted on Tuesday November 06, 2018

Sorrento Therapeutics, Inc. (SRNE) ("Sorrento") announced today the release of data from a phase 1b clinical trial administering anti-CEA CAR-T by utilizing a unique Pressure-Enabled Drug Delivery (PEDD) manufactured by TriSalus™ Life Sciences. The preliminary data for the Hepatic Immunotherapy for Metastases (HITM-SURE) clinical trial results will be presented in a poster at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held November 7-11 in Washington, DC. Five patients, four pancreatic and one colorectal, with carcinoembryonic antigen–positive (CEA+), unresectable stage IV adenocarcinoma with liver metastases, who had failed one or more lines of systemic chemotherapy, each received three hepatic artery infusions of Sorrento autologous anti-CEA CAR-T cells using the Hepatic Immunotherapy for Metastases (HITM) method.


Sorrento Therapeutics Announces the Initiation of Dosing in Its Anti-CD38 CAR-T Phase 1 Clinical Study for Relapsed or Refractory Multiple Myeloma
Posted on Thursday November 01, 2018

Sorrento Therapeutics, Inc. (SRNE), an innovative immunotherapy company, announced today that the first patients were dosed in a Phase 1 study to evaluate the safety and efficacy of CD38 CAR-T therapy in relapsed or refractory multiple myeloma patients at two clinical sites – University of Pennsylvania (UPenn) in Philadelphia and Roger Williams Medical Center in Rhode Island. The CD38 CAR-T cells manufactured at both Sorrento cGMP facilities (San Diego, CA and Providence, RI) met all release specifications and were used in the study. This study is the first US-based clinical trial targeting CD38 using an autologous CAR-T cell therapy.


Research Report Identifies Sorrento Therapeutics, Hurco Companies, Veritiv, Park Electrochemical, VBI Vaccines, and PennantPark Floating Rate Capital with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
Posted on Thursday October 25, 2018

NEW YORK, Oct. 25, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.